Pain management and beyond: Evolving concepts and treatments involving cyclooxygenase inhibition

Journal of Pain and Symptom Management

Volumn 24, Issue 1 SUPPL. 1, 2002, Pages

  Staats, Peter S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Celecoxib; Coxibs; Cyclooxygenase (COX) 2; Etoricoxib; Pain; Parecoxib; Rofecoxib; Valdecoxib

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; IBUPROFEN; KETOROLAC; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; VALDECOXIB;

ALZHEIMER DISEASE; ANXIETY; ARTHRITIS; CANCER; CHRONIC PAIN; CLINICAL TRIAL; COLON CANCER; CONFERENCE PAPER; DEPRESSION; ENZYME INHIBITION; HEALTH CARE COST; HUMAN; MEDICAL CARE; MONOTHERAPY; PAIN; UNITED STATES;

CYCLOOXYGENASE INHIBITORS; HUMANS; PAIN;

EID: 0036666081     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0885-3924(02)00413-X     Document Type: Conference Paper

References (36)

1. Foley K.M. Pain. Bennett J.C., Plum F. Cecil Textbook of Medicine. 20th ed:1996;100-107 W.B. Saunders Company; Philadelphia, PA.
2. American Pain Society. Pain assessment and treatment in the managed care environment. A position statement from the American Pain Society. American Pain Society Web site. Available at: http://www.ampainsoc.org/managedcare/position . htm. Accessed November 5, 2001.
3. Won A., Lapane K., Gambassi G.et al. Correlates and management of nonmalignant pain in the nursing home. J Am Geriatr Soc. 47:1999;936-942.
4. International Association for the Study of Pain, Subcommittee on Taxonomy Part II. Pain terms. a current list with definitions and notes on usage Pain. 6:1979;249-252. [updated 1982,1986].
5. Hendler NH, Kozixowsici JG. Overlooked physical diagnoses in chronic pain patients involved in litigation. Mensana Clinic Web site. Available at: http://www.mensanaclinic.com/articles/overlooked.htm . Accessed October 14, 2001.
6. Staats P.S., Hekmat H., Staats A.W. The psychological behaviorism theory of pain. a basis for unity Pain Forum. 5:1996;194-207.
7. Bostrom M. Summary of the Mayday Fund Survey. public attitudes about pain and analgesics J Pain Symptom Manage. 13:1997;166-168.
8. Van Roenn J.H., Cleeland C.S., Gonin R.et al. Physician attitudes and practice in cancer pain management. Ann Intern Med. 119:1993;121-126.
9. Cleeland C.S., Gonin R., Hatfield A.K.et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med. 330:1994;592-596.
10. Beilin B, Bessler H, Maibord E, et al. Postoperative pain management: effects on the immune system. American Society of Anesthesiologists Annual Meeting; October 14-18, 2000; San Francisco, CA. Abstract A-846.
11. MayoClinic.com. Managing pain: attitude, medication and therapy are keys to control. Mayo Clinic Web site. Available at: http://www.mayoclinic.com/home?id =HQ01055. Accessed October 15, 2001.
12. Staats P.S., Hekmat H., Sauter P.et al. The effects of alcohol celiac block, pain, and mood on longevity in patients with unresectable pancreatic cancer. a double-blind, randomized, placebo-controlled study Pain Med. 2:2001;28-34.
13. Nugent K.P., Spigelman A.D., Phillips R.K.S. Tissue prostaglandin levels in familial adenomatous polyposis patients treated with sulindac. Dis Colon Rectum. 39:1996;659-662.
14. Thun M.J., Namboodiri M.M., Heath C.W. Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 325:1991;1593-1596.
15. DuBois R.N., Radhika A., Reddy B.S.et al. Increased cyclooxygenase-2 levels in carcinogen- induced rat colonic tumors. Gastroenterology. 110:1996;1259-1262.
16. Tsujii M., Kawano S., Tsuji S.et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 93:1998;705-716.
17. Williams C.S., Tsujii M., Reese J.et al. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest. 105:2000;1589-1594.
18. Chan T.A., Morin P.J., Vogelstein B.et al. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA. 95:1998;681-686.
19. Kawamori T., Rao C.V., Seibert K.et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 58:1998;409-412.
20. Jenkins C.A., Bruera E. Nonsteroidal anti-inflammatory drugs as adjuvent analgesics in cancer patients. Palliat Med. 13:1999;183-196.
21. McDonnell F.J., Sloan J.W., Hamann S.R. Advances in cancer pain management. Curr Pain Headache Rep. 5:2001;265-271.
22. Andersen K., Launer L.J., Ott A.et al. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study. Neurology. 45:1995;1441-1445.
23. Stewart W.F., Kawas C., Corrada M.et al. Risk of Alzheimer's disease and duration of NSAID use. Neurology. 48:1997;626-632.
24. Hoozemans J.J., Rozemuller A.J., Janssen I.et al. Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. Acta Neuropath (Berl). 101:2001;2-8.
25. Yasojima K., Schwab C., McGeer E.G.et al. Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain Res. 830:1999;226-236.
26. Eikelenboom P., Rozemuller A.J.M., Hoozemans J.J.M.et al. Neuroinflammation and Alzheimer's disease. clinical and therapeutic implications Alzheimer Dis Assoc Disord. 14:2000;S54-S61.
27. McGeer P.L. Cyclo-oxygenase-2 inhibitors. Rationale and therapeutic potential for Alzheimer's disease. Drugs & Aging. 17:2000;1-11.
28. Pasinetti G.M., Aisen P.S. Cyclooxygenase-2 expression is increased in frontal cortex in Alzheimer's disease. Neuroscience. 87:1998;319-324.
29. Pennisi E. Building a better aspirin. Science. 280:1998;1191-1192.
30. The Canadian Study of Health and Aging The Canadian Study of Health and Aging. Risk factors for Alzheimer's disease in Canada Neurology. 44:1994;2073-2080.
31. Fiechtner JJ, Sikes D, Recker D. A double-blind, placebo-controlled dose ranging study to evaluate the efficacy of valdecoxib, a novel COX-2 specific inhibitor, in treating the signs and symptoms of osteoarthritis of the knee. European League Against Rheumatism; June 13-16, 2001; Prague, Czech Republic. Abstract OP0048.
32. Leese PT, Recker D, Kuss ME. A double-blind, placebo-controlled study to evaluate the effects of valdecoxib, a novel COX-2 specific inhibitor, on platelet function in the elderly. European League Against Rheumatism; June 13-16, 2001; Prague, Czech Republic. Abstract SAT0057.
33. Jain K.K. Evaluation of intravejnous parecoxib for the relief of acute post-surgical pain. Expert Opin Invest Drugs. 9:2000;2717-2723.
34. Riendeau D., Percival M.D., Brideau C.et al. Etoricoxib (MK-0633). preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2 J Pharmacol Exp Ther. 296:2001;558-566.
35. Curtis SP, Fisher C, Kafka S, et al. Treatment with etoricoxib (MK-0663), a COX-2 selective inhibitor, resulted in clinical improvement in knee osteoarthritis (OA) over 52 weeks. European League Against Rheumatism; June 13-16, 2001; Prague, Czech Republic. Abstract SAT0064.
36. Curtis SP, Maldonado-Cocco J, Losada BR, et al. Treatment with etoricoxib (MK-0663), a COX-2 selective inhibitor, resulted in maintenance of clinical improvement in rheumatoid arthritis. European League Against Rheumatism; June 13-16, 2001; Prague, Czech Republic. Abstract FRI0030.